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Abstract
Background: Dopamine receptor 2 agonists (D2-ags) inhibit vascular endothelial growth factor (VEGF) secretion in
luteinized granulosa cells (LGCs) both in vitro and in vivo. However, the mechanism of D2 regulation of the VEGF/
VEGF Receptor 2 (VEGFR-2) pathway remains to be elucidated. We sought to determine the effects of D2 signaling
on VEGF transcription and translation in LGCs, with the expectation of identifying potential D2-ag-based therapies
for ovarian hyperstimulation syndrome (OHSS).
Findings: LGCs from egg donors were cultured with chorionic gonadotropin (hCG) in the presence of Actinomycin-D
(ActD) or Brefeldin-A (BFA) to evaluate the effects of a D2-ag, cabergoline (Cb2), on VEGF secretion. The contribution of
the conventional Gi/Go, Gz and AKT/β-Arrestin pathways in the VEGF regulation was assessed by adding pertussis toxin
(PTX), phorbol 12-myristate 13-acetate (PMA), or wortmannin (WT). While Cb2 inhibited VEGF secretion by interfering
with VEGF peptide translation and secretion, inhibition of conventional D2 transduction pathways did not reverse Cb2-
mediated inhibition of VEGF secretion.
Conclusions: The effects of D2-ag on VEGF translation and secretion are mediated by D2 signaling pathways that have
yet to be described. We found that D2-ag inhibits VEGF secretion at the post-transcriptional level, suggesting that D2-ag
treatment should be combined with therapies that inhibit VEGF transcription, such as the employment of LH or GnRH
for triggering ovulation, to improve the efficacy of OHSS prevention.
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Findings
Ovarian hyperstimulation syndrome (OHSS) is an iatro-
genic complication of ovarian stimulation associated with
the use of human chorionic gonadotropin (hCG), is char-
acterized by an increase in vascular permeability (VP) [1].
Vascular endothelial growth factor (VEGF) is an import-
ant component in the development of OHSS [2, 3]. Be-
sides, it has been demonstrated that hCG administration
increases VEGF mRNA expression in luteinized granulosa
cells (LCGs) [4, 5]. Several studies have attempted to avoid
an increase in VEGF while employing GnRH agonists to
induce ovulation [6, 7]; however, this strategy does not
totally avoid OHSS onset [8], leaving a need for treatments
that block VEGF/VEGF receptor 2 (VEGFR2) signaling
completely.
Several in vivo [9, 10] and in vitro studies [11] have
suggested a role for dopamine in the regulation of the
VEGF/VEGFR2 pathway. Interestingly, high levels of
dopamine are present in follicular fluid and human ovar-
ian biopsies [12, 13], and dopamine receptors have been
found on human granulosa cells (GCs) [14]. Previous
studies suggest a role for dopamine receptor agonist
(D2-ag) in preventing VP increases [15, 16] by inhibiting
VEGF secretion [17, 18]. However, D2-ag has previously
been shown to block the onset of early-stage OHSS in
50 % of women at risk for developing the condition, but
it was not effective in preventing the late onset form
[19]. Understanding the molecular mechanisms involved
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in D2 regulation of VEGF is critical to elucidating the
role of D2-ag in OHSS prevention. Therefore, the goal
of this study was to determine the molecular mechanism
through which D2-ag inhibits VEGF secretion and to
establish which D2 signaling pathways described in D2-
expressing cells (Gi/Go, Gz and AKT/β-Arrestin) [20]
are involved in the regulation of VEGF secretion.
LGCs were obtained from 24 egg donors [aged 25–30
years, oocytes retrieved = 10–15, estrogen (E2) <
2000 pg/mL, body mass index (BMI) < 30]. Cells were
isolated by filtering [21], then washed and cultured as
described below in the different studies. Written in-
formed consent was provided by all participants, and
the study protocol was approved by ethics committee
of IVI Valencia.
VEGF mRNA is not altered by D2-agonist (Cabergoline)
Previous studies have suggested that VEGF inhibition by
D2-agonist, cabergoline (Cb2), is not exerted at the tran-
scriptional level [14, 15], so we evaluated whether the
half-life of VEGF mRNA remained unaffected by D2-ag
administration to LGCs. LGCs (N = 6) were pre-incubated
with 5 μg/mL Actinomycin-D (ActD) (Sigma-Aldrich, St.
Louis, MO) for 2 h to inhibit de novo transcription. Super-
natant was removed and LGCs were incubated in the
presence or absence of Cb2 (100 μM; Pharmacia &
Upjohn, North Peapack, NJ, USA) with 5 IU/mL hCG
(Profasi; Serono Laboratories, Madrid, Spain) and 5 μg/mL
ActD for 1, 2, or 4 h. VEGF (Hs00900055_m1) and β-actin
(Hs99999903_m1) expression levels were estimated by
quantitative QF-RT-PCR using TaqMan® Gene Expression
Assays (Applied Biosystems, Carlsbad, CA, USA). No sig-
nificant differences were observed by a Student’s t-test in
VEGF mRNA (data not shown) or in transcript stability in
Cb2-treated LGCs compared to Cb2-untreated LGCs
(Fig. 1). These results support our previous suspicious
about Cb2 does not affect at transcriptional level.
D2-ag interferes with VEGF protein production and secretion
To determine whether Cb2 has translational or post-
translational effects on VEGF production, LGCs (N = 6)
were pre-incubated with a protein secretion inhibitor,
Brefeldin-A (BFA; 10 μg/mL) (Sigma-Aldrich, St. Louis,
US, A), for 1 h. Subsequently, LGCs were incubated in
the presence or absence of Cb2 (100 μM) with 5 IU/mL
hCG with or without 10 μg/mL BFA for 8 h. Extracellu-
lar and intracellular VEGF levels were measured using
ELISA kits (R&D Systems, Minneapolis, US). Intracellu-
lar VEGF was confirmed by immunofluorescence using
anti-VEGF antibody (10 μg/mL; R&D Systems Minneapolis,
MN) and AlexaFluor594 antibody (1:500; R&D Systems
Minneapolis, US). A fluorescence microscope was used to
observe fluorescence (Nikon Eclipse E400, Japan), and im-
ages were acquired with a digital camera (Olympus, Tokyo,
Japan). Signal intensity was assessed by Matlab (Worcester,
MA), as previously described [22]. The Student’s t-test was
used for statistical analysis and a p-value less than 0.05 was
considered statistically significant.
In the absence of BFA, extracellular VEGF levels in
LGCs not treated with Cb2 were higher than intracellu-
lar VEGF levels, suggesting that most of the VEGF pro-
duced by LGCs were secreted (Fig. 2a, c). However, in
Cb2-treated LGCs, extracellular and intracellular VEGF
levels were similar. Intracellular VEGF levels in these
cells were higher than in Cb2-untreated cells (Figs. 2a, c
and 3a, b), suggesting that Cb2 interferes with the secre-
tion of VEGF in LGCs and most of the VEGF produced
is not secreted.
When protein secretion was inhibited by BFA, intracel-
lular VEGF levels were lower in Cb2-treated than in un-
treated LGCs (Figs. 2b, c and 3a, b), suggesting that D2-ag
also acts by inhibiting VEGF peptide production. Al-
though there are studies suggesting that VEGF secretion
can be regulated by the dopaminergic system [9, 10], none
describe the mechanism how D2-agonists inhibit VEGF.
In this regard, this is the first study showing that VEGF in-
hibition by D2-ag is specifically exerted at the post-
transcriptional level with effect in of both peptide transla-
tion and subsequent releases once it has been produced,
suggesting that D2-ag treatment should be combined with
therapies to inhibit VEGF transcription, such as LH or
GnRH agonists treatment for triggering ovulation, to
improve the efficacy of OHSS prevention [6, 7].
Fig. 1 VEGF mRNA is not altered by the dopamine receptor 2 agonist
Cabergoline. Time-course experiments designed to study the effects of
the dopamine receptor 2 agonist (D2-ag) Cabergoline (Cb2) on VEGF
mRNA stability (expressed as the percentage of VEGF mRNA degradation)
in LGCs. LGCs (n=6) were pre-incubated with actinomycin D (ActD), then
treated with Cb2, hCG, and ActD for 1, 2, or 4 h or untreated. The amount
of VEGF cDNA at time point 0 was assigned a value of 100 and the
percentage of degraded mRNA was estimated according to variations in
the Ct determined by QF-RT-PCR. No significant differences in VEGF mRNA
stability were observed in LGCs treated with Cb2 compared to
untreated LGCs
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Fig. 2 Post-transcriptional regulation of VEGF by the dopamine receptor 2 agonist, Cabergoline. Intracellular and extracellular quantification of VEGF by
ELISA in LGCs (n = 6) cultured for 8 h in hCG with or without Cb2 in the (a) absence or (b) presence of BFA. c Intracellular, extracellular, and total VEGF
levels expressed as pg/mL (mean ± SD). In the absence of BFA (−) extracellular VEGF in Cb2-untreated LGCs were higher than intracellular VEGF levels.
However, in the presence of BFA (+) the intracellular VEGF in Cb2-treated LGCs is lower than in Cb2-untreated cells. ǂp < 0.05 compared to VEGF levels
in Cb2-treated LGCs vs Cb2-untreated LGCs; *p < 0.05 compared to intracellular vs extracellular VEGF levels in absence of BFA
Fig. 3 Intracellular VEGF levels in LGCs cultured with the dopamine receptor 2 agonist, Cabergoline. a Representative immunofluorescence images of
intracellular VEGF staining in fixed and permeabilized LGCs (n=6) pre-incubated with BFA and then incubated in the presence or absence of Cabergoline (Cb2)
with hCG plus or minus BFA. b VEGF immunofluorescence quantification as assessed by Matlab, expressed as eu/pixel. In the absence of BFA (−), intracellular
VEGF levels in Cb2-treated LGCs were higher than the VEGF levels in Cb2-untreated LGCs. However, in the presence of BFA (+) the intracellular VEGF levels in
Cb2-treated cells were lower than vehicle-treated cells. *p<0.05 compared to Cb2-untreated conditions
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The role of the conventional D2 transduction pathways in
the modulation of VEGF secretion mediated by D2-ag
To determine whether the conventional D2 transduction
pathways (Fig. 4a) described in D2 expressing cells [16]
are involved in D2-mediated post-transcriptional VEGF
regulation, LGCs (N = 6) were incubated with 5 IU/mL
hCG in the presence or absence of Cb2 (100 μM) with
or without 200 ng/mL pertussis toxin (PTX; a Gi/o
pathway inhibitor), 100 ng/mL phorbol 12-myristate
13-acetate (PMA; Gz pathway inhibitor) or 10 μM
wortmannin (WT; a AKT/β-arrestin complex inhibi-
tor) (Sigma-Aldrich, St. Louis, MO, USA) for 48 h.
ELISA kit was used to quantify protein production and
secretion and a Student’s t-test was used to determine
statistical significance. Inhibition of these three differ-
ent pathways failed to counteract the effects of Cb2 on
the ability of LGCs to secrete VEGF (Fig. 4b).
Based on our previous findings [17] it is unlikely that the
D2 receptor is not involved in the process. Since the Gi/o,
Gz, and AKT/β-arrestin signaling pathways are common
intermediaries, it is possible that its inhibition might also
be acting on pathways other than those transduced by D2,
which might be involved in the VEGF regulation in LGCs.
Therefore, it could explain why was not observe a counter-
acting increase in VEGF in response to treatment with
PTX, PMA, or WT. The VEGF inhibition observed may be
a result of D2-agonist-mediated transduction pathways that
have yet to be described or alternative mechanisms that
could be acting in well-known VEGF signaling pathways,
such as FAK and MAPK pathways [23], PCL/PKC/Sp1 and
adenylate cyclase/PKA/CREB pathways [24], or PI3k/AKT
pathway [25]. We are unaware whether VEGF regulation
by D2-ag is a universal mechanism of angiogenesis control
in many types of cells and conditions. If so, our findings,
even if non-conclusive, could be useful at least to identify
possible candidates involved in the process.
D2-agonists have also been considered for the treat-
ment of tumorigenic conditions, such as ovarian cancer
[26], in which the deregulation of the VEGF/VEGFR-2
pathways plays a major role. In this regard, investigation
Fig. 4 D2-downstream pathway inhibitors do not affect LGC VEGF secretion in vitro. a Conventional pathways through which D2 signals are transduced and
the inhibitors commonly used to block them; PTX=pertussis toxin, WT=wortmannin, and PMA=phorbol 12-myristate 13-acetate (circles indicate inhibitory
actions). Each of these compounds inhibits one of the D2-downstream pathways. b VEGF secretion levels measured by ELISA (expressed as picograms
per milliliter) from LGCs (n = 6) cultured with hCG in the presence or absence of Cabergoline (Cb2) and PTX, WT, or PMA. Inhibitors of D2-downstream
pathways did not reverse the effect of D2-ag on VEGF secretion. *p < 0.01, compared to the (control) D2-ag treated (blank bar) group
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of the mechanism by which VEGF secretion is regulated
by the dopaminergic system is needed to provide a basis
for more specific therapies to treat diseases related to
VEGF-mediated vascular angiogenesis, including OHSS.
Based on our findings, D2-ag in conjunction with clinical
strategies aimed at reducing VEGF mRNA levels may pro-
vide a more powerful inhibitory effect on VEGF and
improve efforts to prevent OHSS.
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